Alzheimer’s breakthrough after drug treatment success
WEB2 days ago · News Science Alzheimer’s breakthrough after drug treatment success Study found that the medication, called RI-AG03, was effective at preventing the buildup of Tau proteins
Alzheimer's 'First' Achieved With Drug That Hits Hotspots
WEB16 hours ago · The compound, called RI-AG03, is a novel peptide inhibitor—a short chain of amino acids designed to block the activity of specific proteins. ... Breaking News (As it Breaks) The Debate (Twice a ...
Dual-Targeting Drug Halts Tau Accumulation in Alzheimer’s
WEB1 day ago · Summary: Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in Alzheimer’s disease. This peptide inhibitor, RI-AG03, effectively prevents Tau buildup in lab studies and fruit flies, offering hope for new Alzheimer’s treatments. Unlike …
Promising 'first' in Alzheimer's drug development | ScienceDaily
WEB1 day ago · The drug, a peptide inhibitor called RI-AG03, was effective at preventing the build-up of Tau proteins in both lab and fruit fly studies. Skip to main content Your source for the latest research news
Alzheimer’s Game Changer: Dual-Action Drug Attacks
WEB2 days ago · A new peptide inhibitor, RI-AG03, targets two key areas of the Tau protein in Alzheimer's disease, showing effectiveness in lab and fruit fly models. This innovative approach could lead to treatments that slow disease progression with minimal side effects. An international team of scientists led
WEBThe drug, a peptide inhibitor called RI-AG03, was effective at preventing the buildup of tau proteins in both lab and fruit fly studies. The research, published in Alzheimer's & Dementia, was led ...
A novel peptide-based tau aggregation inhibitor as a potential ...
WEBRI-AG03 also rescues a biosensor cell line that stably expresses Tau repeat domains with the P301S mutation fused to Cer/Clo and rescues aggregation-dependent phenotypes in vivo, suppressing neurodegeneration and extending lifespan. Collectively our data describe several properties and attributes of RI-AG03 that make it a promising disease ...
Promising ‘first’ in Alzheimer’s drug develop | EurekAlert!
WEB2 days ago · News Release 3-Oct-2024 Promising ‘first’ in Alzheimer’s drug development Peer-Reviewed Publication. Lancaster University. image: Dr Anthony Aggidis. view ... Testing RI-AG03.
Promising ‘first’ in Alzheimer’s drug develop | EurekAlert!
WEB2 days ago · Testing RI-AG03 The paper describes how RI-AG03 was first developed by Dr Aggidis, in the laboratory of the late Prof David Allsop, using computational biology at Lancaster University, where it ...
Promising ‘first’ in Alzheimer’s drug development
WEB2 days ago · Testing RI-AG03. To test its effectiveness in cells within a living organism, researchers at the University of Southampton then gave the drug to fruit flies that had pathogenic Tau. ... Back to News. Our research represents an important step toward creating treatments that can prevent the progression of diseases like …
- Some results have been removed